{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower and upper limit not calculated due to insufficient number of events.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, lower and upper limit not calculated due to insufficient number of events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"133"},{"groupId":"OG001","value":"129"}],"units":"Participants"}],"description":"Time to histological transformation is defined as from the first dose date of maintenance therapy to the time of histological transformation as measured based on documentation of histological transformation (as assessed by the investigator). Analysis was based on Kaplan Meier estimates.\n\nIn case of clinical suspicion of transformation, including rapid disease progression, unexpected changes in \"B\" symptoms or rapidly increasing LDH, a biopsy should be performed. In this clinical trial, histological transformation will be considered disease progression. This endpoint will not be calculated for participants randomized with transformed Follicular Lymphoma (tFL).","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and Arm B without transformed Follicular Lymphoma (tFL)","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy to the time of histological transformation (up to approximately 432 weeks)","title":"Time to Histological Transformation","type":"SECONDARY","unitOfMeasure":"Weeks"}